Not Yet RecruitingNot Applicable

Low-dose Colchicine for CABG Graft Failure Prevention

China622 participantsStarted 2026-09-01

Plain-language summary

This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Be male or female, aged 18 years or older;
✓. Within 3 days after successful isolated coronary artery bypass grafting (CABG);
✓. Sign informed consent;

Exclusion criteria

✕. Severe valvular heart disease requiring concomitant or staged valvular surgery;
✕. History of non-skin cancer in the past 3 years;
✕. Inflammatory bowel disease or chronic diarrhea;
✕. Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);
✕. Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities (Hemoglobin \<100g/L or hematocrit \< 30% or \> 52% or white blood cell count \< 3×109/L or platelet count \< 100×109/L);
✕. Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m² (based on the CKDEPI formula);
✕. Serum alanine aminotransferase and/or aspartate aminotransferase levels greater than 2 times the upper limit of the normal range, accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders (INR\>1.5) (except for elevated glutamic oxalacetic transaminase associated with myocardial infarction);
✕. Decline in cognitive function due to inability to perform basic activities of daily living independently;

What they're measuring

graft failure rate

Timeframe: 2 year after randomization

Trial details

NCT IDNCT07569328

SponsorBeijing Anzhen Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-09-01

Contact for this trial

Xiaoli Liu, PhD, MD

8613581633895 liuxiaoli@ccmu.edu.cn

View on ClinicalTrials.gov More CAD - Coronary Artery Disease trials